René Roy completed his Ph.D. in medicinal carbohydrate chemistry
from Université de Montréal in 1980. He is a professor emeritus in the Department of
Chemistry, at the Université du Québec à Montréal (UQAM). He is the founder and former director of PharmaQAM, a biopharmaceutical research center based at UQAM, focusing on the discovery of
new bioactive molecules, their mechanism of action, and the vectorization of
drugs. He is a pioneer in the development of synthetic glycoconjugate vaccines
both for human and veterinary health, having co-developed the first and sole
marketed semi-synthetic vaccine for human use, preventing bacterial meningitis
and pneumonia in developing countries. He has published over 400 scientific peer reviewed publications. His current interests concern cancer vaccines, liposomal nanoparticles for drug delivery, and glycodendrimers. He is also co-founder of Glycovax Pharma Inc. which is presently undergoing clinical Phase I vaccine trials against Covid-19.
René Roy completed his Ph.D. in medicinal carbohydrate chemistry
from Université de Montréal in 1980. He is a professor emeritus in the Department of
Chemistry, at the Université du Québec à Montréal (UQAM). He is the founder and former director of PharmaQAM, a biopharmaceutical research center based at UQAM, focusing on the discovery of
new bioactive molecules, their mechanism of action, and the vectorization of
drugs. He is a pioneer in the development of synthetic glycoconjugate vaccines
both for human and veterinary health, having co-developed the first and sole
marketed semi-synthetic vaccine for human use, preventing bacterial meningitis
and pneumonia in developing countries. He has published over 400 scientific peer reviewed publications. His current interests concern cancer vaccines, liposomal nanoparticles for drug delivery, and glycodendrimers. He is also co-founder of Glycovax Pharma Inc. which is presently undergoing clinical Phase I vaccine trials against Covid-19.